ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
Zim Laboratories reported FY26 revenue of ₹3,744M, flat YoY, impacted by geopolitical issues in the MENA region and EU GMP constraints. Strategy focuses on remediation and transitioning from R&D to execution.
Zim Laboratories reported FY26 revenue of ₹3,744 Mn with 11.1% EBITDA margin. Strategy shifts towards innovative products (NIP/OTF) despite regulatory headwinds and geopolitical logistics challenges.